Disclosed is a method for evaluating the ability of a chemical substance or a chemical composition to prevent muscle fatigue and damage induced by physical exertion in humans; edible composition including at least one salt of a multivalent metal cation, at least one compound selected between vitamin E or vitamin E acetate, at least one edible polyphenol compound selected from compounds of the flavonol family, compounds of the anthocyanin family, compounds of the phenolic acid family and compounds of the flavonol family and/or the glucosylated derivatives thereof, in which the molar ratio/is of at least 0.50 and not more than 2.00; its use as a food supplement or for preparing a food supplement composition or as a drug for preventing muscle fatigue and/or muscle damage induced by physical exertion, in a method for the treatment of the human body by therapy.

An isolated pluripotent trophoblast stem (TS) cell preparation, and methods of preparing the cell preparation and a disease model for a pregnancy related disorder are provided. The cell preparation includes cells that are capable of indefinite proliferation in vitro in an undifferentiated state and capable of differentiation into cells of the trophoblast lineage in vitro or in vivo.

Disclosed is a method for evaluating the ability of a chemical substance or a chemical composition to prevent muscle fatigue and damage induced by physical exertion in humans by comparing the effect the chemical substance or a chemical composition has on a combination of three biological markers in cultured human primary skeletal muscle cells.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

This disclosure describes portable bio-nano-chip assays, methods and compositions for diagnosing and assessing pathogen-mediated diseases or infections at point-of-care using biological samples. The assays, methods and compositions provide in a more convenient, less expensive, and less time-consuming sampling and analysis.

The present invention relates generally to methods and materials pertaining to assays, for example immunoassays, for biomarkers in body fluids e.g. blood. The invention also relates to diagnostic or screening methods for infections, and methods of differentiating between infectious and non-infectious conditions in mammals, particularly equines, for monitoring response to anti-infective/antibiotic therapy. The invention further relates to a test fluid collection system adapted to permit dilution and analysis of the collected test fluid. The invention further relates to monitoring exertional rhabdomyolysis in equines, and assay devices for all these things.

Disclosed herein anti-TNF therapy companion diagnostics (e.g., a predictive biomarker panel) for management of Crohn's Disease (CD). The disclosed companion diagnostics may be used to identify an appropriate treatment for a patient, and includes, for example, in vitro diagnostic tests or devices that provide information for the use of an anti-TNF therapy. The disclosed methods may be used, in certain aspects, for the identification of patients likely to respond, or as not likely to respond to an anti-TNF agent. The use of the disclosed methods may allow for dose determination, discontinuation, or the administration of combinations of therapeutic agents.

The invention relates to a method and kit for determining a likelihood of a human subject with asymptomatic tuberculosis (TB) infection or suspected TB infection progressing to active tuberculosis disease, the method comprising detecting a presence or level of a first and a second pair of protein biomarkers selected from Complement Component 9 (C9) and Complement C1q Tumor Necrosis Factor-Related Protein 3 (C1qTNF3); and C9 and Creatine Kinase M- and B-type (CKMB) in a sample from the subject.

A creatine kinase isoenzyme latex-enhanced immunoturbidimetric assay kit, comprising a first reagent and a second reagent. The first reagent comprises a buffer solution, an electrolyte, polyethylene glycol, a surfactant, a preservative, a blocking agent, and a protective agent. The second reagent comprises a buffer solution, polystyrene latex particles coated with a creatine kinase isoenzyme antibody, the creatine kinase isoenzyme antibody on the latex particles, a protective agent, a stabilizer, and a preservative.

Systems and methods for using an indium oxide field-effect transistor. A method includes applying phosphonic acid to a nanoribbon of the indium oxide field-effect transistor. The method also includes preparing the nanoribbon with capture antibodies corresponding to a biomarker. The method also includes applying a fluid sample containing at least one biomarker to the nanoribbon. The method also includes preparing the nanoribbon with secondary antibodies corresponding to the biomarker. The method also includes applying a protein solution to the nanoribbon. The method also includes detecting the presence of the at least one biomarker when a reactive solution is applied to the nanoribbon.